NCT04624217View on ClinicalTrials.gov

A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

November 24, 2020

Primary Completion Date

September 16, 2021

Study Completion Date

February 8, 2023

Conditions

Pancreatic Cancer

Interventions

DRUG

SHR-1701

PDL1/TGFβ

Trial Locations (2)

Unknown

Beijing Cancer Hospital, Beijing

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY